Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Profit After Tax: 2012-2024

Historic Profit After Tax for Rocket Pharmaceuticals (RCKT) over the last 13 years, with Dec 2024 value amounting to -$258.7 million.

  • Rocket Pharmaceuticals' Profit After Tax rose 24.56% to -$50.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$240.9 million, marking a year-over-year increase of 6.65%. This contributed to the annual value of -$258.7 million for FY2024, which is 5.35% down from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Profit After Tax stood at -$258.7 million for FY2024, which was down 5.35% from -$245.6 million recorded in FY2023.
  • Rocket Pharmaceuticals' Profit After Tax's 5-year high stood at -$139.7 million during FY2020, with a 5-year trough of -$258.7 million in FY2024.
  • Moreover, its 3-year median value for Profit After Tax was -$245.6 million (2023), whereas its average is -$242.1 million.
  • Data for Rocket Pharmaceuticals' Profit After Tax shows a maximum YoY tumbled of 80.79% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Rocket Pharmaceuticals' Profit After Tax stood at -$139.7 million in 2020, then declined by 21.02% to -$169.1 million in 2021, then plummeted by 31.23% to -$221.9 million in 2022, then declined by 10.70% to -$245.6 million in 2023, then fell by 5.35% to -$258.7 million in 2024.